Opinion
Video
Clinical Outcomes of Ultra-Low PSA Responses in Patients With mHSPC Receiving Darolutamide Plus ADT
Author(s):
Research reveals that lower PSA levels in metastatic hormone-sensitive prostate cancer significantly delay disease progression and improve patient outcomes.
Video Player is loading.
Ultra-Low PSA Responses and Clinical Outcomes
Key Themes:
- Correlation between achieving PSA <0.02 ng/mL and clinical outcomes
- Impact on time to progression and radiographic progression-free survival (rPFS)
- Overall survival trends in relation to PSA response
Expert Insights:
- Dr Shore presented data demonstrating that patients achieving ultra-low PSA levels (<0.02 ng/mL) experienced improved clinical outcomes.
The analysis showed correlations between ultra-low PSA and important end points including time to progression, rPFS, and overall survival trends
Related Videos
Adam Weiner, MD, on therapeutic decision-making in metastatic prostate cancer
Real-World Safety of Androgen Receptor Inhibitors in Nonmetastatic Castration-Resistant Prostate Cancer
Fred Saad, MD, FRCP, reacts to FDA approval of darolutamide in mCSPC
The Role of Bone-Targeted Therapies
Topline Results From Recent NMIBC Trials
Exploring Nadofaragene Firadenovec: Ongoing Trials and Study Designs
First-Line mHSPC Therapy: AR Inhibitors vs Chemotherapy
Using Ultrasensitive PSA Assays in Routine Practice
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
Related Content
